Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

03 Sep 2015 Evaluate

Glenmark Pharmaceuticals has informed about a Press Release dated September 03, 2015 titled ‘Glenmark’s novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe’.

The above information is a part of company’s filings submitted to BSE.


 

Peers
Company Name CMP
Sun Pharma. Inds. 1762.95
Dr. Reddys Labs. 1338.50
Cipla 1357.00
Lupin 1998.00
Zydus Lifesciences 1186.00
View more..